PharmaBoardroom today releases its new 46-page Healthcare & Life Sciences Review Hong Kong 2017.
This report offers companies, investors, policymakers, and stakeholders crucial insight into the rich ecosystem of pharmaceuticals, biotech, and healthcare companies in Hong Kong, based on in-depth interviews conducted with leaders and pioneers across the value chain, from government representatives, country managers of the world’s leading biopharmaceutical companies, representatives from local SMEs and service providers, and the leading figures from Hong Kong’s rich network of research and educational institutes.
Healthcare & Life Sciences Review Hong Kong 2017 also contains features on Hong Kong’s regionally-leading healthcare system; how its innovative companies are looking not only to Mainland China to expand, but also further afield; the region’s potential as a clinical trials destination; and the possibility of Hong Kong birthing the first biotech ‘unicorn’ startup company with a value of over USD 1 billion.
The report features in-depth interviews with:
Dennis Lo, CUHK
Michael Tsui, Rehab Robotics
Scott Curley, AstraZeneca
Christopher Cheng, HKIB
“Hong Kong is in a sweet spot because we are part of the world’s second largest economy … Around the world, we are the only country where the West and East literally converge. We have the best of both worlds in terms of access to the mainland Chinese market, talent and resources as well as international standards and conventions.”
Charles Ng, Invest Hong Kong
“Looking at the government’s policies and the number of people interested in biotechnology, the percentage of interest and enterprise has critically improved. Even traditional businesses are beginning to acknowledge the power of biotechnology.”
Albert Yu Cheung-Hoi, HKBIO
“I think that an original innovation company requires four major ingredients for survival: money, manpower, information, and incentive. For each of those ingredients, I daresay Hong Kong is better than Taiwan and Singapore. To add to that, in Hong Kong, the Closer Economic Partnership Agreement (CEPA) grants us unfettered access to the mainland China market, which is huge.
Jun Wang, GeneHarbor Biotechnologies
“Hong Kong, like most mature markets, is driven by the introduction of innovative products. Developing and implementing the right market access strategy is therefore very important.”
Alexandre de Muralt, Merck
Click here to register and download the report.